ライフサイエンスコーパス: glycogen synthase kinase 3beta

1 horylation and impaired binding to GSK3beta (glycogen synthase kinase 3beta).

2 ) transcriptional activity via inhibition of glycogen synthase kinase 3beta.

3 7, p38 mitogen-activated protein kinase, and glycogen synthase kinase 3beta.

4 ociated with activated AKT and inhibition of glycogen synthase kinase 3beta.

5 r export, which however, were independent of glycogen synthase kinase 3beta.

6 x ratio, phosphorylation of Akt, ERK1/2, and glycogen synthase kinase 3beta.

7 on of 4E-binding protein 1 and activation of glycogen synthase kinase 3beta.

8 pstream signaling pathways known to regulate glycogen synthase kinase-3beta.

9 n E2 expression and independently of p53 and glycogen synthase kinase-3beta.

10 ed by application of a specific inhibitor of glycogen synthase kinase 3beta (6-bromoindirubin-3'-oxim

11 increase in phospho-beta-catenin and active glycogen synthase kinase 3beta, a kinase known to target

12 cortical and hippocampal phosphorylation of glycogen synthase kinase-3beta, a constitutively active

13 marked reduction of inactive phosphorylated glycogen synthase kinase-3beta, a negative regulator of

14 orylation of the inhibitory Ser-9 residue of glycogen synthase kinase-3beta, a primary Tau kinase inv

15 atty acids, and this suppression depended on glycogen synthase kinase 3beta activation and induction

16 Moreover, JNK and glycogen synthase kinase 3beta activation was significan

17 NF-kappaB activation by sorafenib requires glycogen synthase kinase 3beta activation, subsequent to

18 au phosphorylation and solubility, increased glycogen synthase kinase 3beta activity, compromised lon

19 protein that plays a key role in attenuating glycogen synthase kinase 3beta activity, leading to aber

20 post-translational mechanism, independent of glycogen synthase kinase-3beta activity regulating beta-

21 ronic inflammation, we found that inhibiting glycogen synthase kinase-3beta activity with lithium red

22 sed p38 mitogen-activated protein kinase and glycogen synthase kinase-3beta activity, which are belie

23 -beta(1-40), phospho-tau(Thr 231) and active glycogen synthase kinase-3beta (aGSK-3beta).

24 gnaling cascade, including phospho-GSK3beta (glycogen synthase kinase-3beta), also show significant d

25 Glycogen synthase kinase-3beta, also called tau phosphor

26 2A and recruits protein phosphatase 2A with glycogen synthase kinase 3beta and beta-catenin, inducin

27 ls (P<0.05), and expressions of proapoptotic glycogen synthase kinase 3beta and caspase 3 were lower

28 Glycogen synthase kinase 3beta and Foxo1 are two PI-3K-r

29 isms involved demonstrate that ASPH binds to glycogen synthase kinase 3beta and inhibits its subseque

30 ibition of ASPH activity, phosphorylation of glycogen synthase kinase 3beta and p16 expression were i

31 king M(1)R were attributed to changes in the glycogen synthase kinase 3beta and protein kinase C acti

32 f kinases including protein kinase B/Akt and glycogen synthase kinase 3beta and regulates cell prolif

33 activation of Akt, leading to inhibition of glycogen synthase kinase-3beta and activation of beta-ca

34 on occurred secondary to the inactivation of glycogen synthase kinase-3beta and an increase in levels

35 attenuated basal phosphorylation of Akt and glycogen synthase kinase-3beta and blocked cardiac prote

36 ulin signaling may lead to overactivation of glycogen synthase kinase-3beta and down-regulation of O-

37 re was an increase in the level of activated glycogen synthase kinase-3beta and enhanced expression o

38 panied by hyperphosphorylation of substrates glycogen synthase kinase-3beta and mammalian target of r

39 at Ser-473 and other ILK targets, including glycogen synthase kinase-3beta and myosin light chain.

40 hase survival pathway, and the inhibition of glycogen synthase kinase-3beta and nuclear factor kappa

41 hase survival pathway, and the inhibition of glycogen synthase kinase-3beta and nuclear factor kappa

42 Wnt/beta-catenin signaling is independent of glycogen synthase kinase-3beta and of the proteasome- an

43 ac1 activation, redox phosphorylation of AKT/glycogen synthase kinase 3beta, and consequent smooth mu

44 t3a (the canonical activator), inhibitors of glycogen synthase kinase 3beta, and small-interfering RN

45 endent kinase 1, protein kinase C theta, and glycogen synthase kinase 3beta, as well as contributing

46 d beta-TrCP and decreased phosphorylation of glycogen synthase kinase 3beta associated with decreased

47 mediated by inhibition of phosphorylation of glycogen synthase kinase 3beta at residue Ser(9).

48 phorylation of Akt/PKB at residue Ser473 and glycogen synthase kinase-3beta at Ser9.

49 ollowed by phosphorylation (inactivation) of glycogen synthase kinase-3beta, at least in part via STA

50 cyclin D1, E-cadherin, beta-catenin, Dvl-1, glycogen synthase kinase-3beta, axin-1, and adenomatous

51 3-kinase, Akt, and Bcl.xL and inhibition of glycogen synthase kinase 3beta besides release of SDF-1a

52 establishing a mechanistic role for the ERK/glycogen synthase kinase 3beta/beta-catenin pathway in t

53 ial-mesenchymal transition by repressing AKT/glycogen synthase kinase-3beta/beta-catenin signaling.

54 reasing Ser9 phosphorylation-inactivation of glycogen synthase kinase 3beta by RBMY, thereby impeding

55 of stable MT subsets through inactivation of glycogen synthase kinase 3beta by the viral Ser/Thr kina

56 Akt murine thymoma viral oncogene homolog-1, glycogen synthase kinase 3beta, cyclin-dependent kinase

57 Downstream of glycogen synthase kinase 3beta, cytoplasmic linker-assoc

58 mylation by Taxol treatment or inhibition of glycogen synthase kinase 3beta decreased the selectivity

59 mpaired insulin signaling, overactivation of glycogen synthase kinase-3beta, decreased levels of majo

60 e kinase 3beta by RBMY, thereby impeding the glycogen synthase kinase 3beta-dependent degradation of

61 Molecularly, ROCK inhibition induced glycogen synthase kinase 3beta-dependent phosphorylation

62 Tau phosphorylation was increased via a glycogen synthase kinase-3beta-dependent mechanism, and

63 inding (CREB) protein levels to decreaseviaa glycogen synthase kinase-3beta-dependent mechanism.

64 In contrast, inhibition of glycogen synthase kinase 3beta did not mimic lithium-ind

65 ver, inhibition of protein phosphatase 1 and glycogen synthase kinase 3beta, downstream targets of Ca

66 ced tumor growth, induced phosphorylation of glycogen synthase kinase 3beta, enhanced p16 expression

67 of several proapoptotic proteins, including glycogen synthase kinase-3beta, FKHR, and MDM-2.

68 ogated insulin-stimulated phosphorylation of glycogen synthase kinase-3beta, forkhead box O1, and mTO

69 sion of insulin receptor, IRS-1, IRS-2, Akt, glycogen synthase kinase-3beta, forkhead box O1, protein

70 ted with release of the inhibitory effect of glycogen synthase kinase 3beta function by decreasing Se

71 ion and completely blocked the inhibition of glycogen synthase kinase-3beta gene transcription.

72 eta-catenin signaling cascades, which switch glycogen synthase kinase 3beta (GSK-3beta) activation on

73 Aberrant glycogen synthase kinase 3beta (GSK-3beta) activity is a

74 Ser215, a consensus phosphorylation site for glycogen synthase kinase 3beta (GSK-3beta) and its primi

75 Phosphorylation of tau at Thr212 and glycogen synthase kinase 3beta (GSK-3beta) at Ser9 was r

76 ction in thrombin-induced phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) at Ser9, whic

77 Glycogen synthase kinase 3beta (GSK-3beta) has been sugg

78 ase A (PKA) activation by cAMP analogues and glycogen synthase kinase 3beta (GSK-3beta) inhibition de

79 Glycogen synthase kinase 3beta (GSK-3beta) is a primary

80 Glycogen synthase kinase 3beta (GSK-3beta) is an enzyme

81 Recent studies have demonstrated that glycogen synthase kinase 3beta (GSK-3beta) is overexpres

82 Here we show that glycogen synthase kinase 3beta (GSK-3beta) is required f

83 In addition, AT7519 inhibited glycogen synthase kinase 3beta (GSK-3beta) phosphorylati

84 ected T cells and reduces phosphorylation of glycogen synthase kinase 3beta (GSK-3beta), a downstream

85 phorylation of PHLPP1 by casein kinase I and glycogen synthase kinase 3beta (GSK-3beta), and activati

86 ylation of Ser-389, a key inhibitory site of glycogen synthase kinase 3beta (GSK-3beta), and this eff

87 olved and show that the Tau-specific kinase, glycogen synthase kinase 3beta (GSK-3beta), is robustly

88 of cyclin B1, cyclin D3, and phosphorylated glycogen synthase kinase 3beta (GSK-3beta), while infect

89 Because beta-catenin is regulated by glycogen synthase kinase 3beta (GSK-3beta)-directed phos

90 plus ends in polarized cells is regulated by glycogen synthase kinase 3beta (GSK-3beta).

91 ion of specific Akt substrates, most notably glycogen synthase kinase 3beta (Gsk-3beta).

92 ound a residue that can be phosphorylated by glycogen synthase kinase 3beta (GSK-3beta).

93 Akt/mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3beta (GSK-3beta)/adenomatous p

94 rom AD patients exhibited elevated levels of glycogen synthase kinase 3beta (GSK-3beta, an enzyme kno

95 APAP treatment to mice caused glycogen synthase kinase-3beta (GSK-3beta) activation an

96 arrest in G1/S phase, mAb16D10 triggering of glycogen synthase kinase-3beta (GSK-3beta) activation, d

97 DA receptors was involved in the increase of glycogen synthase kinase-3beta (GSK-3beta) activity, whi

98 is revealed that leptin and DEX converged on glycogen synthase kinase-3beta (GSK-3beta) and beta-cate

99 Treatment with NO donor led to activation of glycogen synthase kinase-3beta (GSK-3beta) and c-Jun N-t

100 events include the proline-directed kinases glycogen synthase kinase-3beta (GSK-3beta) and cyclin-de

101 rexpression of TDP-43 leads to activation of glycogen synthase kinase-3beta (GSK-3beta) and that GSK-

102 In AD, kinases such as glycogen synthase kinase-3beta (GSK-3beta) are believed

103 c entry in Xenopus oocytes, we characterized glycogen synthase kinase-3beta (GSK-3beta) as a dampener

104 We show glycogen synthase kinase-3beta (GSK-3beta) as a target g

105 on of downstream signaling molecules Akt and glycogen synthase kinase-3beta (GSK-3beta) at Ser9, and

106 inked to phosphorylation and inactivation of glycogen synthase kinase-3beta (GSK-3beta) at serine 9,

107 dated AD targets beta-secretase (BACE-1) and glycogen synthase kinase-3beta (GSK-3beta) by attacking

108 regulation of galectin-3 resulted in AKT and glycogen synthase kinase-3beta (GSK-3beta) dephosphoryla

109 We examined the role of glycogen synthase kinase-3beta (GSK-3beta) inhibition in

110 Remarkably, in the uninjured retina, glycogen synthase kinase-3beta (GSK-3beta) inhibition wa

111 In addition, application of glycogen synthase kinase-3beta (GSK-3beta) inhibitor com

112 etin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiC

113 Herein we report that glycogen synthase kinase-3beta (GSK-3beta) is phosphoryl

114 The inactivation of glycogen synthase kinase-3beta (GSK-3beta) is proposed a

115 Activity of glycogen synthase kinase-3beta (GSK-3beta) is required f

116 We found that TGF-beta1 induced glycogen synthase kinase-3beta (GSK-3beta) phosphorylati

117 as a putative molecular recognition site for glycogen synthase kinase-3beta (GSK-3beta) phosphorylati

118 Recent reports suggest that glycogen synthase kinase-3beta (GSK-3beta) plays a key r

119 decreased by POX in that phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) was decreased

120 Furthermore, activation of glycogen synthase kinase-3beta (GSK-3beta) was required

121 PI3K, AKT, and glycogen synthase kinase-3beta (GSK-3beta) were phosphor

122 osphorylation (and hence, the activation) of glycogen synthase kinase-3beta (GSK-3beta) with a declin

123 We identify glycogen synthase kinase-3beta (GSK-3beta), an anti-hype

124 neurin, apoptosis-stimulated kinase (ASK-1), glycogen synthase kinase-3beta (GSK-3beta), GATA4, and c

125 sis coli tumor suppressor protein (APC), and glycogen synthase kinase-3beta (GSK-3beta), which could

126 atocytes, which led to a delayed increase in glycogen synthase kinase-3beta (GSK-3beta)-mediated hepa

127 demonstrate that alcohol intake also blocks glycogen synthase kinase-3beta (GSK-3beta)-phosphorylati

128 teins, which were predicted to be targets of glycogen synthase kinase-3beta (GSK-3beta).

129 ase that targets specific substrates such as glycogen synthase kinase-3beta (GSK-3beta).

130 hase and the phosphorylation (inhibition) of glycogen synthase kinase-3beta (GSK-3beta).

131 s was identified as the pro-apoptotic factor glycogen synthase kinase-3beta (GSK-3beta).

132 Dyrk1A primed its further phosphorylation by glycogen synthase kinase-3beta (GSK-3beta).

133 this effect was mediated by the tau kinase, glycogen synthase kinase-3beta (GSK-3beta).

134 hase and the phosphorylation (inhibition) of glycogen synthase kinase-3beta (GSK-3beta).

135 ein function are via a pathway that involves glycogen synthase kinase-3beta (GSK-3beta).

136 ological or genetic inhibition of tau kinase glycogen-synthase-kinase-3beta (GSK-3beta).

137 ), agonists of the Wnt/beta-catenin pathway (glycogen synthase kinase 3beta [GSK-3beta] inhibitors),

138 udy phosphorylated PKC zeta (p-PKC zeta) and Glycogen Synthase Kinase 3beta (GSK3 beta) were found to

139 lizes PRLr via inhibitory phosphorylation of glycogen synthase kinase-3beta (GSK3 beta) on Ser(9).

140 Consequently, GRbeta-Ad mice had increased glycogen synthase kinase 3beta (GSK3beta) activity and r

141 the c-Jun N-terminal kinase (JNK)-dependent glycogen synthase kinase 3beta (GSK3beta) activity on do

142 , N-methyl-d-aspartate receptor function, or glycogen synthase kinase 3beta (GSK3beta) activity or ex

143 ver, hypoinsulinemia leads to an increase in glycogen synthase kinase 3beta (GSK3beta) activity that,

144 ssociated with insulin resistance, decreased glycogen synthase kinase 3beta (GSK3beta) activity, acti

145 (NF-kappaB) pathway and in the induction of glycogen synthase kinase 3beta (GSK3beta) activity, resu

146 uroprotective factor that acts by modulating glycogen synthase kinase 3beta (GSK3beta) activity.

147 of beta-catenin by enhancing binding between glycogen synthase kinase 3beta (GSK3beta) and beta-caten

148 phosphorylation-mediated interaction between glycogen synthase kinase 3beta (GSK3beta) and c-Myc.

149 degradation of beta-catenin mediated by the glycogen synthase kinase 3beta (GSK3beta) and destructio

150 tcome on different molecular targets such as glycogen synthase kinase 3beta (GSK3beta) and Forkhead b

151 Cellular targets of Li(+), such as glycogen synthase kinase 3beta (GSK3beta) and G proteins

152 tion of downstream effectors of Akt, such as glycogen synthase kinase 3beta (GSK3beta) and mammalian

153 factors combined with LIF and inhibitors of glycogen synthase kinase 3beta (GSK3beta) and mitogen-ac

154 egrons that bind Cdc4 when phosphorylated by Glycogen Synthase Kinase 3beta (GSK3beta) and p38 MAPK,

155 Unexpectedly, RNAi-mediated silencing of glycogen synthase kinase 3beta (GSK3beta) and phosphoino

156 oteasomal degradation via phosphorylation by glycogen synthase kinase 3beta (GSK3beta) and recognitio

157 ted protein kinase kinase 4 (MKK4), JNK, and glycogen synthase kinase 3beta (GSK3beta) and thereby de

158 (APC), casein kinase 1alpha (CK1alpha), and glycogen synthase kinase 3beta (GSK3beta) and undergoes

159 In silico kinase prediction revealed glycogen synthase kinase 3beta (GSK3beta) as the most li

160 TGF-beta1 expression and hyperacetylation of glycogen synthase kinase 3beta (GSK3beta) at residue K15

161 tein, HSC70) and causes dephosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser 9 by re

162 ects against hepatic steatosis by inhibiting glycogen synthase kinase 3beta (GSK3beta) by enhancing s

163 e tested the hypothesis that inactivation of glycogen synthase kinase 3beta (GSK3beta) by high glucos

164 n this issue, Wu et al. demonstrate that the glycogen synthase kinase 3beta (GSK3beta) controls micro

165 In this study, we demonstrate that glycogen synthase kinase 3beta (GSK3beta) directly phosp

166 Glycogen synthase kinase 3beta (GSK3beta) has been ident

167 Glycogen synthase kinase 3beta (GSK3beta) has been shown

168 Cyclin-dependent kinase 5 (cdk5) and glycogen synthase kinase 3beta (GSK3beta) have been impl

169 phosphorylation by casein kinase 1 (CK1) and glycogen synthase kinase 3beta (GSK3beta) in a phosphode

170 quent signaling, causing overt activation of glycogen synthase kinase 3beta (GSK3beta) in nerves of m

171 synthesis is associated with inactivation of glycogen synthase kinase 3beta (GSK3beta) in renal cells

172 y, we provide evidence to support a role for glycogen synthase kinase 3beta (GSK3beta) in such regula

173 In this study, we investigated the role of glycogen synthase kinase 3beta (GSK3beta) in the surviva

174 Glycogen synthase kinase 3beta (GSK3beta) inhibitors, es

175 A member of this family is glycogen synthase kinase 3beta (GSK3beta) interaction pr

176 We show that glycogen synthase kinase 3beta (GSK3beta) interacts with

177 Glycogen synthase kinase 3beta (GSK3beta) is a constitut

178 Inhibition of glycogen synthase kinase 3beta (GSK3beta) is a shared ac

179 As glycogen synthase kinase 3beta (GSK3beta) is an importan

180 Glycogen synthase kinase 3beta (GSK3beta) is involved in

181 At low glucose levels, glycogen synthase kinase 3beta (GSK3beta) is known to ph

182 Glycogen synthase kinase 3beta (GSK3beta) may be critica

183 ar carcinoma-derived KLF6 mutations affect a glycogen synthase kinase 3beta (GSK3beta) phosphorylatio

184 inked kinase (ILK), leading to modulation of glycogen synthase kinase 3beta (GSK3beta) phosphorylatio

185 ates beta-TrCP recognition and encompasses a glycogen synthase kinase 3beta (GSK3beta) phosphorylatio

186 of TGF-beta receptors and p38 MAPK increased glycogen synthase kinase 3beta (GSK3beta) phosphorylatio

187 This was associated with decreased levels of glycogen synthase kinase 3beta (GSK3beta) protein and mR

188 Here we report that glycogen synthase kinase 3beta (GSK3beta) regulates dend

189 In this study, we demonstrate that glycogen synthase kinase 3beta (GSK3beta) regulates ST2L

190 d by the core clock oscillator BMAL1 and AKT/glycogen synthase kinase 3beta (GSK3beta) signaling path

191 Knockdown of glycogen synthase kinase 3beta (GSK3beta) significantly

192 ically, leptin stimulates phosphorylation of glycogen synthase kinase 3beta (GSK3beta) via Akt activa

193 [e.g., strong bias toward phosphorylation of glycogen synthase kinase 3beta (GSK3beta) via the full-l

194 Glycogen synthase kinase 3beta (GSK3beta) was recently i

195 In contrast, the activity of glycogen synthase kinase 3beta (GSK3beta), a negatively

196 Glycogen synthase kinase 3beta (GSK3beta), a serine/thre

197 5-HT levels is accompanied by activation of glycogen synthase kinase 3beta (GSK3beta), a signaling m

198 kt, mammalian target of rapamycin complex 1, glycogen synthase kinase 3beta (GSK3beta), and CREB.

199 e IGF-I, IGF binding protein-1 (IGFBP-1) and glycogen synthase kinase 3beta (GSK3beta), as one major

200 Psychotropic medications target glycogen synthase kinase 3beta (GSK3beta), but the funct

201 ivation, which results in hyperactivation of glycogen synthase kinase 3beta (GSK3beta), followed by p

202 kt pathway, leading to the downregulation of glycogen synthase kinase 3beta (GSK3beta), in wild type

203 compelling evidence supporting key roles for glycogen synthase kinase 3beta (GSK3beta), mitochondrial

204 Mechanical signals can inactivate glycogen synthase kinase 3beta (GSK3beta), resulting in

205 The phosphorylation is catalyzed by glycogen synthase kinase 3beta (GSK3beta), ultimately re

206 fate through the translational regulation of glycogen synthase kinase 3beta (GSK3beta), we investigat

207 hic signaling intermediates, such as Akt and glycogen synthase kinase 3beta (GSK3beta), were dephosph

208 y sites in the N-terminus of beta-catenin as glycogen synthase kinase 3beta (GSK3beta), which are rec

209 dent on LFA-1/ICAM-1-induced inactivation of glycogen synthase kinase 3beta (GSK3beta), which is medi

210 APC also induced phosphorylation of Ser-9 in glycogen synthase kinase 3beta (GSK3beta), which was blo

211 s strictly regulated in normal cells via the glycogen synthase kinase 3beta (GSK3beta)- adenomatous p

212 n this paper, we show a critical role of the glycogen synthase kinase 3beta (GSK3beta)-cyclin D3 path

213 Glycogen synthase kinase 3beta (GSK3beta)-dependent beta

214 PI exposure abrogated glycogen synthase kinase 3beta (GSK3beta)-mediated degra

215 Glycogen synthase kinase 3beta (GSK3beta)-mediated phosp

216 1 interacts with Nrf2 and stabilizes it from glycogen synthase kinase 3beta (GSK3beta)-mediated phosp

217 FN signaling pathways occurs at the point of glycogen synthase kinase 3beta (GSK3beta)-TANK-binding k

218 n (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3beta (GSK3beta).

219 by increasing the stability and activity of glycogen synthase kinase 3beta (GSK3beta).

220 the expression of Akt, or the inhibition of glycogen synthase kinase 3beta (GSK3beta).

221 branching is mediated by the protein kinase glycogen synthase kinase 3beta (GSK3beta).

222 t VRK2 activity was negatively controlled by glycogen synthase kinase 3beta (GSK3beta).

223 s of the casein kinase 1 (CK1) family and by glycogen synthase kinase 3beta (GSK3beta).

224 oteins adenomatosis polyposis coli, Axin and glycogen synthase kinase 3beta (GSK3beta).

225 g protein binding protein kinase A (PKA) and glycogen synthase kinase 3beta (GSK3beta).

226 These include protein kinase A (PKA) and glycogen synthase kinase 3beta (GSK3beta).

227 ivation and this occurs in part by targeting glycogen synthase kinase 3beta (GSK3beta).

228 inhibition of the tumor suppressors PTEN and glycogen synthase kinase 3beta (GSK3beta).

229 6)), FoxO1 (Ser(319)), FoxO4 (Ser(197)), and glycogen synthase kinase 3beta (GSK3beta; Ser(9)).

230 Glycogen synthase kinase-3beta (GSK3beta) activity is in

231 nted pre-synaptic protein deficit, decreased glycogen synthase kinase-3beta (GSK3beta) activity, and

232 chanism by which the serine-threonine kinase glycogen synthase kinase-3beta (GSK3beta) affects surviv

233 Glycogen synthase kinase-3beta (GSK3beta) and casein kin

234 of signaling proteins, including fyn kinase; glycogen synthase kinase-3beta (GSK3beta) and cyclin-dep

235 global ischemia promotes early activation of glycogen synthase kinase-3beta (GSK3beta) and forkhead t

236 finding is the pronounced downregulation of glycogen synthase kinase-3beta (Gsk3beta) and upregulati

237 Glycogen synthase kinase-3beta (GSK3beta) has diverse bi

238 The prolyl isomerase Pin1 and glycogen synthase kinase-3beta (GSK3beta) have been show

239 Here we demonstrate that hyperactivity of glycogen synthase kinase-3beta (GSK3beta) in the atrium

240 While glycogen synthase kinase-3beta (GSK3beta) is known to pa

241 Glycogen synthase kinase-3beta (GSK3beta) plays a critic

242 PDGF-DD induced glycogen synthase kinase-3beta (GSK3beta) Ser(9) phospho

243 uclear Nrf2 export/degradation machinery via glycogen synthase kinase-3beta (Gsk3beta) signaling was

244 Glycogen synthase kinase-3beta (GSK3beta) suppresses tum

245 at PAD4 recognizes, binds, and citrullinates glycogen synthase kinase-3beta (GSK3beta), both in vitro

246 lted in increased phosphorylation of Akt and glycogen synthase kinase-3beta (GSK3beta), leading to en

247 ase activity of the serine/threonine kinase, glycogen synthase kinase-3beta (GSK3beta), via its Ser9

248 ylation of kinesin-1 light chain-2 (KLC2) by glycogen synthase kinase-3beta (GSK3beta).

249 ivation of Akt and a prolonged activation of glycogen synthase kinase-3beta (GSK3beta).

250 nstitutively active serine/threonine kinase, glycogen synthase kinase-3beta (GSK3beta).

251 tion and insulin secretion via regulation of glycogen synthase kinase-3beta (GSK3beta).

252 s (ankyrin G, EB1) were knocked down or when glycogen synthase kinase-3beta (GSK3beta; an AD-associat

253 cogene/protein kinase B [AKT], inhibition of glycogen synthase kinase-3beta [GSK3beta], a 20-fold up-

254 x and is required for phosphorylation of the glycogen synthase kinase-3beta homologue Zeste-white 3 k

255 tion of Akt and increased phosphorylation of glycogen synthase kinase 3beta in an arrestin signalsome

256 elet activating factor-induced activation of glycogen synthase kinase 3beta in platelets in a manner

257 Overexpression of Snail1 and inhibition of glycogen synthase kinase-3beta in colorectal tumor cells

258 Investigation of Akt and glycogen synthase kinase-3beta in wild-type and CCM hear

259 nalling proteins, protein kinase B (Akt) and glycogen synthase-kinase 3beta, in maternal liver (P < 0

260 Such glycogen synthase kinase-3beta inactivation causes chang

261 ta-catenin expression and stabilization in a glycogen synthase kinase 3beta-independent manner.

262 Sustained glycogen synthase kinase 3beta inhibition and Mcl-1 expr

263 in, and that beta-catenin activation through glycogen synthase kinase 3beta inhibition leads to FANCC

264 cin complex 1 (TORC1) activity, resulting in glycogen synthase kinase 3beta inhibition, beta-Catenin

265 -beta stimulation of human keratinocytes, by glycogen synthase kinase-3beta inhibition in several epi

266 d human T cells by treatment either with the glycogen synthase kinase 3beta inhibitor TWS119 or the p

267 igated, and we demonstrate that VPA, a known glycogen synthase kinase 3beta inhibitor, blocks platele

268 erentiated hPSCs into mesoderm cells using a glycogen synthase kinase-3beta inhibitor for 3 days, the

269 mbinant Wnt3a protein or CHIR-99021 (CHIR, a glycogen synthase kinase-3beta inhibitor) caused a dose-

270 naling pathway involving caspase-3, Akt1 and glycogen synthase kinase-3beta is an important mediator

271 L is stabilized in a complex with axin1 when glycogen synthase kinase-3beta is overexpressed.

272 ha/wrd pathway in the motoneuron antagonizes glycogen synthase kinase-3beta kinase activity to preven

273 no changes in Ctnnb1 expression, activity of glycogen synthase kinase-3beta, known to phosphorylate a

274 involves activation of ERK and inhibition of glycogen synthase kinase 3beta leading to cytoprotection

275 decreased DJ-1 and increased phosphorylated glycogen synthase kinase 3beta levels may account for im

276 n showed AQP1 interaction with beta-catenin, glycogen synthase kinase 3beta, LRP6, and Axin1.

277 hosphorylation, downstream phosphosubstrates glycogen synthase kinase 3beta, mammalian target of rapa

278 Wnt/beta-catenin pathway by inactivation of glycogen synthase kinase 3beta of NKT cells.

279 G-132 but was independent of the activity of glycogen synthase kinase 3beta or MALT-1, both of which

280 l as by inhibition of the Akt-GSK-3beta (Akt-glycogen synthase kinase-3beta) pathway.

281 in endothelial cells as reflected in Akt and glycogen synthase kinase 3beta phosphorylation, Ras-rela

282 ment, and reduced Akt (protein kinase B) and glycogen synthase kinase 3beta phosphorylation.

283 However, glycogen synthase kinase-3beta phosphorylation at S9 is

284 OE mouse hearts had increased basal Akt and glycogen synthase kinase-3beta phosphorylation comparabl

285 of cyclin-dependent protein kinase 5 (Cdk5), glycogen synthase kinase 3beta, protein phosphatase 1, o

286 f the endogenous MTA1s or ERK, or its target glycogen synthase kinase 3beta resulted in a substantial

287 activator of beta-catenin via inhibition of glycogen synthase kinase-3beta, reversed the inhibition

288 te-mediated phosphoinositide 3-kinase (PI3K)/glycogen synthase kinase 3beta signaling and decreased a

289 on of GABAergic transmission via D2 receptor-glycogen synthase kinase-3beta signaling dramatically re

290 oxygen species and restored dysregulated Akt-glycogen synthase kinase-3beta signaling in the hippocam

291 egradation can be triggered by inhibitors of glycogen synthase kinase 3beta, such as lithium, and als

292 TGF-beta1-induced phosphorylation of Akt and glycogen synthase kinase-3beta, suppressed cyclin D1 exp

293 ll as the cyclin-dependent kinase family and glycogen synthase kinase 3beta that also utilize the C-t

294 tube formation, whereas knockdown of RhoA or glycogen synthase kinase 3beta that are inactivated afte

295 on, and increased phosphorylation of Akt and glycogen synthase kinase-3beta, ultimately resulting in

296 in total and phosphorylated Akt, as well as glycogen synthase kinase 3beta, via a caspase-dependent

297 The phosphorylation and inactivation of glycogen synthase kinase-3beta was dependent on mammalia

298 ization of Nmyc is mediated by activation of glycogen synthase kinase 3beta, which targets Nmyc for p

299 Akt deactivates glycogen synthase kinase-3beta, which permits Nrf2 nucle

300 d to the phosphorylation and inactivation of glycogen synthase kinase-3beta, which resulted in inhibi